Serum sclerostin in acute kidney injury patients

Abdulazim, Dina O.; Amin, Mohamed; Elhadidy, Samir; Samir, Hussien H; Salem, Mona M; ElAzim, Ibrahim M Abd; Hawary, Khaled El Sayed El; Din, Usama A Sharaf El

doi:10.1016/j.nefro.2021.01.010

Cited by 4 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, since there are few studies in this area, only 4 studies with 5 cohorts were included in this paper. During study selection, one was eliminated because it is a non-quantitative description 28 , and the other cohort study of 428 people in Egypt 29 found that 25(OH)D levels of patients in the AKI group were lower than those in the non-AKI group, presenting the results in medium (50% IQR).We attempted to contact the author for 25–75% IQR data but unfortunately did not receive a response. It is not included in our study and may could lead to bias.…”

Section: Discussionmentioning

confidence: 99%

Serum vitamin D levels and acute kidney injury: a systemic review and meta-analysis

Zhang

Jiang

Song

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Numerous researches have evaluated the prevalence and clinical outcome of vitamin D deficiency in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). But the quantitative vitamin D status in acute kidney injury (AKI) patients and its relationship with prognosis remains controversial. We conducted this systemic review and meta-analysis to assess the quantitative difference of vitamin D status, including serum 25(OH) D and 1,25(OH)2D levels, between AKI patients and non-AKI controls, and further explore whether vitamin D status can be clearly correlated with the mortality of AKI. Major databases, including PubMed, Web of Science and EBSCO, were searched until 1st September 2021. All published observational studies related to vitamin D and AKI According to predefined inclusion and exclusion criteria were extracted. Meta-analyses were performed using Review Manager 5.3.5. Four studies including five cohorts were included with a total of 413 patients. The serum 25(OH)D levels showed no statistically significant difference in AKI patients and non-AKI controls. On the other hand, the serum 1,25(OH)2D levels were significant lower in AKI patients than in non-AKI controls (MD = − 17.79, 95% CI = − 32.73 to − 2.85, P = 0.02). As for the relationship between serum vitamin D status and AKI patients’ mortality, we were unable to give a consistent conclusion based on current limited and conflict study results. Our meta-analysis suggested that serum 1,25(OH)2D levels, rather than 25(OH)D, is significantly lower in AKI patients. The relationship between vitamin D status and clinical outcome of AKI remains controversial based on current evidence. Future comprehensive studies are required to confirm these relations and to elucidate potential mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum vitamin D levels and acute kidney injury: a systemic review and meta-analysis

Zhang

Jiang

Song

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Very interesting results have been reported in preclinical [16] and clinical [17] studies of acute kidney injury (AKI). Increased serum sclerostin concentrations (approximately 3-fold increase compared to kidney-healthy controls) have been found in de novo (due to sepsis) or in acute-on-chronic kidney disease [17]. Therefore, even short-term uremia seems to lead to increased sclerostin expression.…”

Section: Serum Sclerostin Is Increased In Ckdmentioning

confidence: 99%

Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease

Cejka

2021

Metabolites

View full text Add to dashboard Cite

The significance of sclerostin for bone and cardiovascular health in patients with chronic kidney disease (CKD) is complex and incompletely understood. Experimental evidence suggests that anti-sclerostin therapy shows diminished efficacy on bone in the setting of CKD. Limited clinical evidence suggests that the osteoanabolic and anti-resorptive activity is attenuated, but hypocalcemia is more prevalent in patients with advanced CKD (eGFR < 30 mL/min) treated with anti-sclerostin (romosozumab) therapy as compared to patients without kidney disease. Furthermore, sclerostin is prominently expressed in uremic arteries. Whether the inhibition of sclerostin has adverse effects on cardiovascular health in CKD is currently unknown. This review summarizes the current understanding of the physiology and pathophysiology of sclerostin in CKD, with a focus on the cardiovascular safety of anti-sclerostin therapy in patients with or without CKD.

show abstract